Loading organizations...
MI Bioresearch functioned as a preclinical contract research organization specializing in immuno-oncology and oncology. It provided comprehensive services to pharmaceutical and biotechnology clients, including human cell line and syngeneic models, in vitro services, in vivo pharmacology, in vivo imaging, and focal beam radiation. This platform yielded cancer biology insights, delivering high-quality, decision-enabling data for therapy.
Founded in 2003 by Patrick McConville and Wilbur R. Leopold III, MI Bioresearch emerged from the insight that specialized preclinical research was vital for drug development. The founders identified a need for advanced modeling and imaging to accelerate oncology discovery. Their expertise bridged the translational gap between early-stage and clinical development.
The company served clients within the pharmaceutical and biotechnology sectors, supporting cancer research. MI Bioresearch’s vision focused on refining preclinical methodologies to offer superior insights into cancer mechanisms and treatment responses, expediting new therapies.
MI Bioresearch has raised $21.0M across 3 funding rounds.
MI Bioresearch has raised $21.0M in total across 3 funding rounds.
MI Bioresearch is a preclinical oncology contract research organization (CRO) specializing in in vivo and in vitro pharmacology services, including advanced imaging technologies for cancer drug development. Formerly known as Molecular Imaging, it provides a bank of human and syngeneic cancer cell line models, supported by platforms like MRI, micro-CT, micro-PET, SPECT, and optical imaging to evaluate sponsor drugs and biologics.[1][2][3] Based in Ann Arbor, Michigan, the company serves pharmaceutical and biotechnology firms by delivering decision-enabling data for preclinical and translational research, and it was acquired by Covance (a LabCorp subsidiary), integrating into a global drug development network.[2][4]
This positions MI Bioresearch as a key enabler in oncology R&D, offering comprehensive services from cell line models to focal beam radiation, with a focus on immuno-oncology models that address complex cancer pharmacology.[1][4]
Founded in 2003 in Ann Arbor, Michigan, MI Bioresearch (originally Molecular Imaging) emerged as a provider of in vivo pharmacology and imaging services tailored to oncology research.[1][3] Specific founders are not detailed in available records, but the company quickly built expertise in preclinical models, attracting early investment from Invest Detroit Ventures and others.[1] A pivotal moment came with its acquisition by Covance, a LabCorp subsidiary, which expanded its reach within a leading drug development ecosystem while preserving its specialized oncology focus.[2][4] This evolution from an independent entity to part of LabCorp's global network marked its growth from niche imaging services to a comprehensive CRO supporting diverse pharma clients.[4]
MI Bioresearch stands out in the preclinical CRO space through these key strengths:
MI Bioresearch rides the wave of surging oncology drug development, fueled by advances in immuno-oncology, biologics, and precision medicine, where preclinical accuracy is critical to reduce clinical failure rates.[1][4] Its timing aligns with market forces like rising R&D investments in cancer therapies—projected to exceed $200B annually by 2025—and the demand for imaging-enhanced models that bridge preclinical to clinical stages.[2][4] By influencing the ecosystem through high-fidelity data for sponsors, it accelerates pipelines for LabCorp clients, while ethical innovations like AI-driven animal welfare set standards in humane research, supporting broader trends in responsible biotech.[5]
MI Bioresearch is poised for expansion within LabCorp's ecosystem, likely integrating more AI and advanced imaging to tackle emerging challenges like multi-omics oncology models and personalized therapies. Trends such as accelerated drug approvals and AI-optimized preclinical testing will amplify its role, potentially evolving its influence toward leading global immuno-oncology CRO services. This builds on its core strength in delivering precise, ethical data that fast-tracks innovations from lab to patient.[5]
MI Bioresearch has raised $21.0M in total across 3 funding rounds.
MI Bioresearch's investors include Arboretum Ventures, Arcus Ventures, Beringea.
MI Bioresearch has raised $21.0M across 3 funding rounds. Most recently, it raised $4.0M Series B in October 2013.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 1, 2013 | $4M Series B | — | Arboretum Ventures, Arcus Ventures, Beringea | Announced |
| Mar 1, 2012 | $10M Series A | — | Arboretum Ventures, Arcus Ventures, Beringea | Announced |
| May 1, 2011 | $7M Series A | — | Arboretum Ventures, Arcus Ventures, Beringea | Announced |
